Figure (IMAGE)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)

Figure

Caption

Optimal dendritic-cell-based antitumor immunotherapy with cDC1 cells requires active mitochondria. Whereas vaccination with normal cDC1 cells efficiently reduces metastasis in B16-OVA tumors, the antitumor efficacy of these cells is diminished when their mitochondria are damaged.

Credit

CNIC

Usage Restrictions

CNIC

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.